ELV vs MET
Elevance Health, Inc. and Metlife Inc., side by side — 10 fiscal years reported in USD, drawn from SEC filings.
At a glance
Most recent reported year
| Metric | ELV | MET |
|---|---|---|
| Revenue | $199.1B | $77.1B |
| Net income | $5.7B | $3.4B |
| Gross margin | 89.4% | — |
| Net margin | 2.8% | 4.4% |
| Return on equity | 13.3% | 12.1% |
| Diluted EPS | $25.21 | $4.71 |
| Dividend / share | — | $2.25 |
| Payout ratio | 27.0% | 44.7% |
| Free cash flow | $3.2B | — |
| Equity | $43.9B | $28.4B |
| Net debt / equity | 0.51× | −0.25× |
| Current ratio | 1.54× | — |
| Revenue CAGR 5y | 10.3% | 2.6% |
| Profit CAGR 5y | 4.4% | −9.0% |
ELV bills 2.6× the revenue of MET, and MET keeps more of each dollar of revenue as profit (4.4% against 2.8%).
The stronger figure of the pair is set in bold. That is arithmetic, not a recommendation — this page does not pick a winner.
Revenue by year
10 years side by side
| Fiscal year | ELV | MET |
|---|---|---|
| FY2025 | $199.1B | $77.1B |
| FY2024 | $177.0B | $71.0B |
| FY2023 | $171.3B | $66.9B |
| FY2022 | $156.6B | $68.8B |
| FY2021 | $138.6B | $68.7B |
| FY2020 | $121.9B | $67.8B |
| FY2019 | $104.2B | $69.6B |
| FY2018 | $92.1B | $67.9B |
| FY2017 | $90.0B | $62.3B |
| FY2016 | $84.9B | $60.8B |
Net income by year
Bottom line
| Fiscal year | ELV | MET |
|---|---|---|
| FY2025 | $5.7B | $3.4B |
| FY2024 | $6.0B | $4.4B |
| FY2023 | $6.0B | $1.6B |
| FY2022 | $5.9B | $5.3B |
| FY2021 | $6.2B | $6.9B |
| FY2020 | $4.6B | $5.4B |
| FY2019 | $4.8B | $5.9B |
| FY2018 | $3.8B | $5.1B |
| FY2017 | $3.8B | $4.0B |
| FY2016 | $2.5B | $850.0M |